Cell Therapeutics raises $40M for drug buy, Pixuvri launch; Exelixis launches 'cabo' Phase III

@FierceBiotech: California's CIRM votes to shift stem cell grants toward clinical development side. More | Follow @FierceBiotech

@JohnCFierce: In fresh setback, Alnylam's most advanced drug flunks PhIIb RSV test. (Not what they need right now.) Item | Follow @JohnCFierce

@RyanMFierce: 23andMe's Google ties make today's news of the gene patent less surprising. News | Follow @RyanMFierce

> Seattle-based Cell Therapeutics ($CTIC) is selling $40 million in shares to an institutional investor. The money will be used to complete the acquisition of S*Bio's pacritinib and launch Pixuvri in Europe. Release

> Exelixis ($EXEL) has launched COMET-1, a Phase III pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer. Release

> Federal regulators have rejected Johnson & Johnson's ($JNJ) application for a once-daily version of the HIV drug Prezista. The pharma company, though, says that it does not need to run any additional studies of the drug. Report

> Repros Therapeutics ($RPRX) says it will need to complete a safety analysis of past trials of oral Proellex before regulators allow it to resume studies of a low-dose version of the therapy. Report

> Medivation ($MDVN) and Astellas say that the FDA agreed that the partners may proceed with an Expanded Access Program for enzalutamide (formerly MDV3100) under a treatment protocol in the U.S., while marketing approval is being sought from the FDA. Release

> Trial vets at Flexion claim PhIIb success with lead osteoarthritis drug. Article

> China readies plan to spur its booming biotech sector. Story

> Bristol-Myers pushes latest blockbuster cancer drug prospect into ASCO spotlight. Report

> BMS creates global cancer drug collaboration. More

Pharma News

@FiercePharma: Endo's lobbying yields a provision in House user-fee bill that could protect its Lidoderm patch--NYT. More | Follow @FiercePharma

> Another FDA warning for J&J's McNeil unit. News

> Endo seeks protections in House FDA reauthorization. Item

> Stada must join the generics buyout binge, CEO says. Story

> How does Genentech like it under Roche's wing? Article

Medical Devices News

@FierceMedDev: For Biosensors, stents and an acquisition helped drive a stellar FY2012. Report | Follow @FierceMedDev

@MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Foundation Medicine launches innovative cancer diagnostic. Story

> GE opens $80 million research center in China. Article

> FDA cites J&J's McNeil-PPC unit for limp lubricants. News

> U.S. House ramps up for device tax repeal vote next week. More

Drug Delivery News

@DamianFierce: Perhaps you can have too much of a good thing. Penn researchers say too many nanocarriers render treatments ineffective: Story | Follow @DamianFierce

> MIT develops needle-free jet injector. More

> Delivery firm seeks $3M for transdermal platform. Story

> West Pharma looks to cash in on biosimilar delivery. Report

> IntelGenx eyes FDA nod with anti-migraine film results. Item

Biomarkers News

> Biomarkers help select the most fertile donors. News

> Jury is still out on value of genetic biomarkers. Story

> Fitness level may be key to surviving breast cancer. More

> Bile duct biomarker screening for fluke-linked cancer. Article

And Finally… Investigators say that there's anecdotal evidence that bariatric surgery can alter the basic biology that triggers diabetes, suggesting a new approach to curing the ailment. Story


Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.